The deterioration of motor skills in Parkinson’s patients is driven by the decline of dopamine production, but researchers in Japan are making exciting progress on a way to potentially arrest the slide. Following promising experiments on monkeys last year, scientists at Kyoto University are now preparing to begin transplanting reprogrammed stem cells into human brains as part of a first-of-a-kind clinical trial.
WideCells Group (LON:WDC) is a worldwide provider of stem cell services headquartered in Manchester, United Kingdom.
We are committed to making a difference in the world of family health protection; providing individuals and families access to affordable stem cell treatments globally.